Open AccessPMON30 Low-dose Infigratinib, an Oral Selective Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor, Demonstrates Activity in a Preclinical Model of Hypochondroplasia
Author(s) -
Carl Dambkowski,
Benoît Demuynck,
Laurence LegeaiMallet,
Léa Loisay
Publication year - 2022
Publication title -
journal of the endocrine society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.046
H-Index - 20
ISSN - 2472-1972
DOI - 10.1210/jendso/bvac150.956
Subject(s) - endochondral ossification , dwarfism , endocrinology , intramembranous ossification , achondroplasia , medicine , fibroblast growth factor receptor , fibroblast growth factor receptor 3 , fibroblast growth factor , tyrosine kinase , phenotype , short stature , biology , receptor , pathology , cartilage , anatomy , genetics , surgery , gene
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom